Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc.

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for allegedly misleading investors about the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. Allegations - The lawsuit claims that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [2]. - The company's public statements were alleged to be materially false and misleading throughout the class period [2]. Recent Developments - On July 18, 2024, Agenus announced the results of an end-of-Phase 2 meeting with the FDA, which advised against submitting results for Accelerated Approval due to concerns that objective response rates may not translate to survival benefits [3]. - Following this announcement, Agenus's stock price dropped by $10.43 per share, a decline of 58.83%, closing at $7.30 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders since its inception in 2002 [5].